WHO ICTRP trial
Phase III clinical trial Oligometastatic and Oligorecurrent PROstate Cancer…
EUCTR2018-004458-14-IT · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2018-004458-14-IT |
|---|---|
| Public title | Phase III clinical trial Oligometastatic and Oligorecurrent PROstate Cancer: enhancing patients’ selection by new ImagiNG biomarkers |
| Scientific title | Phase III clinical trial Oligometastatic and Oligorecurrent PROstate Cancer: enhancing patients’ selection by new ImagiNG biomarkers - PROvING |
| Primary sponsor | AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no |
| Countries | Italy |
| Conditions | Prostate cancer MedDRA version: 21.0 Level: PT Classification code 10036911 Term: Prostate cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT… |
| Interventions | Product Name: 68Ga-complex of Glu-NH-CO-NH-Lys-(Ahx)-HBED-CC Product Code: [68GaPSMA-11] Pharmaceutical Form: Solution for injection INN or Proposed INN: 68Ga-complex of Glu-NH-CO-NH-Lys-(Ahx)-HBED-CC Current Sponsor code: [68Ga]PSMA-11… |
| Registration date | Oct 21, 2020 |
| Target size | 246 |
| Secondary IDs | PROvING |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: